demonstrated that selective activation of Nrf2 presents an attractive therapeutic approach for alleviating aberrant airway inflammation in COPD by restoring macrophage function.[63] This supports our application of ONX‐0194 for COPD treatment. This evidence concerns the gene NFE2L2 and chronic obstructive pulmonary disease.